Happy to share that our paper RECAP will be presented as an oral at the 8th Workshop on Clinical NLP at LREC 2026. Proud of Adarsh Srinivasan, who led this as part of his undergrad thesis. Thanks also to @notumarafzal@UzairSarfraz7@IrbazRiaz@BenZhou96 for making it happen.
Happy to share that our paper RECAP will be presented as an oral at the 8th Workshop on Clinical NLP at LREC 2026. Proud of Adarsh Srinivasan, who led this as part of his undergrad thesis. Thanks also to @notumarafzal@UzairSarfraz7@IrbazRiaz@BenZhou96 for making it happen.
It’s hard to put into words how much this journey has meant to me. I came into this lab not knowing anyone, and now I leave with a family. A part of me will always remain here. Grateful beyond words to @IrbazRiaz for the mentorship, guidance, care, and lessons I’ll never forget.
Honored to present my work at GU ASCO 2026. Inspiring to see the great work being carried out by so many researchers across the world! Super grateful to my mentors @IrbazRiaz@ewan_cobran for their unwavering support and guidance!
In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival. Full phase 3 EMBARK trial results and Research Summary: https://t.co/jwAROfr840
In the phase 3 CORALreef Lipids trial, the oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by 57% at 24 weeks and also lowered non-HDL cholesterol, apolipoprotein B, and lipoprotein(a). Adverse events were similar in the two groups. Full trial results: https://t.co/o5RS02KCWi
Editorial: Exploring a New “Reef” in Dyslipidemic Risk Reduction https://t.co/W3KfZHkxMD
A privilege to meet and attend the @MayoCancerCare Grand Rounds by Dr. Sumanta Pal @montypal here at Mayo Clinic, Arizona.
Very fortunate to be able to listen and learn from Dr. Pal!
We’re excited to share an updated release of our open-source MatchMiner-AI (MM-AI) pipeline for cancer clinical trial matching!
MM-AI is a research tool directed towards identifying reasonable clinical trials for patients based on their unstructured medical records.
A massive new study on peak performance included 34,000 international top performers: Nobel laureates, renowned classical music composers, Olympic champs, and the world’s best chess players. It shows early specialization is a trap, and the road to greatness is long and varied.
🧵 New survey reframes how we evaluate medical LLMs: judge by Levels of Autonomy (L0–L3)
and tie claims to clinical risk and oversight, not just leaderboard scores. Moves evaluation from
benchmarks to real workflows.
📄https://t.co/w8tPgmX0MU
Today, the UN family mourns the loss of Dr. Jane Goodall.
The scientist, conservationist and UN Messenger of Peace worked tirelessly for our planet and all its inhabitants, leaving an extraordinary legacy for humanity and nature.
What a privilege to host @anantm at our #AI lab @MayoCancerCare.His stories and life lessons left our trainees inspired. Moments like these remind us why mentorship matters. Deeply grateful for his time and wisdom #Mentorship#Inspiration